BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 24661650)

  • 1. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes.
    Barker CA; Postow MA
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):986-97. PubMed ID: 24661650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for the management of advanced melanoma: the next steps.
    Zikich D; Schachter J; Besser MJ
    Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma immunotherapy: historical precedents, recent successes and future prospects.
    Raaijmakers MI; Rozati S; Goldinger SM; Widmer DS; Dummer R; Levesque MP
    Immunotherapy; 2013 Feb; 5(2):169-82. PubMed ID: 23413908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
    Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
    G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of metastatic melanoma: an overview.
    Bhatia S; Tykodi SS; Thompson JA
    Oncology (Williston Park); 2009 May; 23(6):488-96. PubMed ID: 19544689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for malignant melanoma.
    Zeiser R; Schnitzler M; Andrlova H; Hellige T; Meiss F
    Curr Stem Cell Res Ther; 2012 May; 7(3):217-28. PubMed ID: 22329580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunotherapy of melanomas].
    Zimmer L; Vaubel J; Schadendorf D
    Hautarzt; 2012 Dec; 63(12):952-8. PubMed ID: 23097082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of distant metastatic disease.
    Schadendorf D; Algarra SM; Bastholt L; Cinat G; Dreno B; Eggermont AM; Espinosa E; Guo J; Hauschild A; Petrella T; Schachter J; Hersey P
    Ann Oncol; 2009 Aug; 20 Suppl 6(Suppl 6):vi41-50. PubMed ID: 19617297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
    Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
    Front Immunol; 2018; 9():411. PubMed ID: 29552014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of melanoma: present options and future promises.
    Rotte A; Bhandaru M; Zhou Y; McElwee KJ
    Cancer Metastasis Rev; 2015 Mar; 34(1):115-28. PubMed ID: 25589384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.
    Lens M; Testori A; Ferucci PF
    Curr Top Med Chem; 2012; 12(1):61-6. PubMed ID: 22196270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the role of ipilimumab in melanoma and first data on new combination therapies.
    Maio M; Di Giacomo AM; Robert C; Eggermont AM
    Curr Opin Oncol; 2013 Mar; 25(2):166-72. PubMed ID: 23299197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
    Cavalcante L; Chowdhary A; Sosman JA; Chandra S
    Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next generation of immunotherapy for melanoma.
    Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
    J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of patients with metastatic melanoma.
    Yu Z; Si L
    Chin Clin Oncol; 2017 Apr; 6(2):20. PubMed ID: 28482673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory therapy for melanoma: ipilimumab and beyond.
    Callahan MK; Postow MA; Wolchok JD
    Clin Dermatol; 2013; 31(2):191-9. PubMed ID: 23438382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma].
    Robert C; Mateus C
    Med Sci (Paris); 2011 Oct; 27(10):850-8. PubMed ID: 22027422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.
    Roszik J; Haydu LE; Hess KR; Oba J; Joon AY; Siroy AE; Karpinets TV; Stingo FC; Baladandayuthapani V; Tetzlaff MT; Wargo JA; Chen K; Forget MA; Haymaker CL; Chen JQ; Meric-Bernstam F; Eterovic AK; Shaw KR; Mills GB; Gershenwald JE; Radvanyi LG; Hwu P; Futreal PA; Gibbons DL; Lazar AJ; Bernatchez C; Davies MA; Woodman SE
    BMC Med; 2016 Oct; 14(1):168. PubMed ID: 27776519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.